Matritech Will Stress BladderChek Rapid Screen Accuracy As Selling Point
This article was originally published in The Gray Sheet
Executive Summary
Matritech will highlight the BladderChek point-of-care bladder cancer screening test's sensitivity, about twice that of standard cytology evaluations, to promote the technology among urologists
You may also be interested in...
Cytogen/Matritech BladderChek
Restructured marketing agreement calls for Cytogen to target oncologists while Matritech focuses on urologists. The point-of-care, urine-based bladder cancer screening test was 510(k)-cleared last July (1"The Gray Sheet" May 5, 2003, p. 25)...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.